http://orcid.org/0000-0003-4266-0771
References
- Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18:156–169.
- Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;135:2641–2648.
- Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis. JAMA Dermatol. 2015;151:616–622.
- Carrascosa JM, Toro Montecinos M, Ballescá F, et al. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. JDT. 2018;29:140–144.
- Takahashi H, Tsuji H, Ishida-Yamamoto A, et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39–42.
- Menting SP, van den Reek JM, Baerveldt EM, et al. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Br J Dermatol. 2015;173:855–857.5.
- Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10.
- Winter ME. Basic clinical pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins. 2004; p. 73–74.
- Kasper LH, Everitt D, Leist TP, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. 2006;22:1671–1678.
- STELARA® [prescribing information]. Horsham, PA: Janssen Biotech, Inc. Issued 9/2016. [cited 2018 Feb 6]. Available from: https://www.stelarainfo.com/pdf/prescribinginformation.pdf
- Spanish registry of systemic treatments in psoriasis, Biobadaderm. Biobadaderm study group. Biobadaderm attribution methods; 2017 [cited 2017 Sept 18]. Available from: https://biobadaser.ser.es/biobadaderm/cgi-bin/upload/documentacion.aspx
- Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:694–709.
- Zhu Y, Wang Q, Frederick B, et al. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two phase 1 studies. Clin Drug Investig. 2013;33:291–301.
- Chiu HY, Chu TW, Cheng YP, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10:e0142930.
- Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31:213–220.